Subscribe to RSS
DOI: 10.1055/a-2548-5404
Exploring the Dual Therapeutic Potential of a Photoactivatable AIEgen in Cancer and Alzheimer’s Disease
The authors acknowledge the financial grants from the Department of Science and Technology (DST), New Delhi, India (projects DST/CRG/2019/002614 and FIST:SR/FST/CS-II/2017/23C), the Department of Electronics and Information Technology, Ministry of Communications and Information Technology (Deity), India (No. 5(1)/2022-NANO), the Indian Council of Medical Research (ICMR) (no. 5/3/8/20/2019-ITR), and the Max-Planck-Gesellschaft (IGSTC/MPG/PG(PKI)/2011A/48). P.G. acknowledges Prime Minister's Research Fellowship (Fellowship No. 1900819), Ministry of Education, India for funding his research.
Abstract
One minimally invasive treatment that may help with Alzheimer’s disease (AD) and cancer is photodynamic therapy (PDT). Side effects are reduced with PDT, which targets cancer cells while preserving healthy tissue. Photo-oxygenation of amyloid-β (Aβ) is considered an efficient way to inhibit Aβ aggregation in AD. In this work, we constructed a photoactivatable aggregation-induced emission probe, 2-(7a-ethoxybenzo[f]indeno[1,2-b]chromen-12(7aH)-ylidene)malononitrile (P1), which exhibited red emission, amyloid targeting ability, good biocompatibility, and photostability, and a remarkable capacity to generate reactive oxygen species. Molecular docking was performed to elucidate the interactions between P1 with Aβ40 and Cathepsin D, confirming its binding efficacy and stability. In vitro studies confirm the therapeutic ability of the probe in PDT. These combined properties highlight the comprehensive dual therapeutic potential of P1 in AD and cancer.
Key words
AIEgen - multifunctional fluorescent probe - reactive oxygen species - cancer photodynamic therapy - Alzheimer’s diseaseSupporting Information
- Supporting information for this article is available online at https:
//doi.org/10.1055/s-0037-1611940.
- Supporting Information
- CIF File
Publication History
Received: 31 December 2024
Accepted after revision: 27 February 2025
Accepted Manuscript online:
28 February 2025
Article published online:
09 April 2025
© 2025. Thieme. All rights reserved
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References and Notes
- 1 Alzheimer’s Dementia 2024; 20: 3708
- 2 Ording AG, Horváth-Puhó E, Veres K, Glymour MM, Rørth M, Sørensen HT, Henderson VW. Alzheimer’s Dementia 2020; 16: 953
- 3 Wu Q, Li Y, Li Y, Wang D, Tang BZ. Mater. Chem. Front. 2021; 5: 3489
- 4 Khatun MN, Nandy S, Roy H, Ghosh SS, Kumar S, Iyer PK. Chem. Sci. 2024; 15: 9298
- 5 Ghosh P, Mukhopadhyay S, Kandasamy T, Mondal S, Ghosh SS, Iyer PK. J. Mater. Chem. B 2025; 13: 1412
- 6 Seo SU, Woo SM, Im S.-S, Jang Y, Han E, Kim SH, Lee H, Lee H.-S, Nam J.-O, Gabrielson E, Min K, Kwon TK. Cell Death Dis. 2022; 13: 115
- 7 Hardy JA, Higgins GA. Science 1992; 256: 184
- 8 Ghosh P, Narang K, Iyer PK. Methods Mol. Biol. 2024; 2761: 337
- 9 Liu H, Li Y, Wei L, Ye Z, Yuan J, Xiao L. Nano Today 2024; 58: 102434
- 10 Liu Z, Ma M, Yu D, Ren J, Qu X. Chem. Sci. 2020; 11: 11003
- 11 Lee BI, Chung YJ, Park CB. Biomaterials 2019; 190: 121
- 12 Ghosh P, Iyer PK. Acc. Mater. Res. 2025; 6: 89
- 13 Ghosh P, Shokeen K, Mondal S, Kandasamy T, Kumar S, Ghosh SS, Iyer PK. ACS Chem. Neurosci. 2024; 15: 268
- 14 Chowdhury SR, Agarwal M, Meher N, Muthuraj B, Iyer PK. ACS Appl. Mater. Interfaces 2016; 8: 13309
- 15 Chowdhury SR, Mukherjee S, Das S, Patra CR, Iyer PK. Chem. Sci. 2017; 8: 7566
- 16 Synthesis of 2-(7a-Ethoxybenzo[f]indeno[1,2-b]chromen-12(7aH)-ylidene)malononitrile (P1). 2-Hydroxy-1-naphthaldehyde (172 mg, 1 mmol) and 2-(3-oxo-2,3-dihydro-1H-inden-1-ylidene)malononitrile (233 mg, 1.2 mmol) were dissolved in absolute ethanol (5 mL) and piperidine (10 μL) was added. The mixture was stirred and heated at 80 °C for 6 h then cooled. The formed solid was filtered, washed with cold ethanol, and dried. Recrystallization from chloroform gave the P1 as orange crystals (yield >80%). 1H NMR (600 MHz, CDCl3): δ = 8.62 (s, 1 H), 8.52 (d, J = 8.0 Hz, 1 H), 8.06 (d, J = 8.4 Hz, 1 H), 7.89 (d, J = 8.8 Hz, 1 H), 7.85 (d, J = 7.5 Hz, 1 H), 7.82 (d, J = 8.0 Hz, 1 H), 7.69 (t, J = 7.5 Hz, 1 H), 7.59 (t, J = 7.4 Hz, 2 H), 7.46 (t, J = 7.4 Hz, 1 H), 7.32 (d, J = 8.8 Hz, 1 H), 3.77 (dd, J = 8.6, 7.2 Hz, 1 H), 3.55 (dd, J = 8.7, 7.1 Hz, 1 H), 0.95 (t, J = 7.1 Hz, 3 H). 13C NMR (151 MHz, CDCl3): δ = 160.13, 153.65, 143.93, 136.41, 134.58, 134.50, 131.55, 131.40, 130.30, 130.06, 129.29, 128.88, 126.76, 125.99, 125.81, 124.65, 122.82, 118.23, 115.70, 114.71, 114.31, 101.21, 77.71, 77.50, 77.29, 72.03, 59.65, 15.47. NMR spectra are shown in Figures S25 and S26. CCDC 2412856 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures. See Figure S27 and Table S1 for crystal structure details.
- 17 Eruslanov E, Kusmartsev S. Methods Mol. Biol. 2010; 594: 57
- 18 Ghosh P, Iyer PK. ACS Appl. Mater. Interfaces 2024; 16: 20034
- 19 Noi K, Ikenaka K, Mochizuki H, Goto Y, Ogi H. Anal. Chem. 2021; 93: 11176
- 20 Sanner MF. J. Mol. Graphics Modell. 1999; 17: 57
- 21 van Meerloo J, Kaspers GJ. L, Cloos J. Methods Mol. Biol. 2011; 731: 231
- 22 Figueroa D, Asaduzzaman M, Young F. J. Pharmacol. Toxicol. Methods 2018; 94: 26